Though OLIG2 has an established role in promoting GBM progression through its effects on glioma stem-like cells (GSCs), Zhang et al. demonstrated a further role for OLIG2 in suppressing antitumor immunity: in human GSCs and GSCs from mouse models of GBM, OLIG2 expression epigenetically repressed the interferon-responsive chemokine CXCL10, thereby limiting cytotoxic T cell infiltration. The gene discussed is OLIG2; the disease is glioma.